Moffitt Presentations at ASCO 2024

Note - all times are listed as CST

Friday, May 31, 2024

Time

Location

Type

Title

Author/Presenter

2:45-5:45 p.m. Hall D1 Oral Abstract Session
Melanoma/Skin Cancers
Zeynep Eroglu (Session Chair, not presenting)

Saturday, June 1, 2024

Time	Location	Type	Title	Author/Presenter
8:00-9:15 a.m.	Hall A	Poster Board #389b	Abstract TPS9612 - First-in-human study of 225actinium mti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM).	Nikhil Khushalani
8:15 - 8:30 a.m.	Arie Crown Theater	Education Session	New Frontiers in Lung Cancer Treatment: Expanding Options Beyond Chemoimmunotherapy	Ben Creelan
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #327	Abstract 9543 - High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.	Ahmad Tarhini
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #100	Abstract 2621 - A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.	Richard Kim
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #389a	Abstract TPS9611 - A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.	Nikhil Khushalani
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #74	Abstract 2595 - Phase 1/2 study of XTX202, a tumor-activated IL-2βγ, in advanced solid tumors.	Jad Chahoud
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #340	Abstract 9556 - Melphalan/hepatic delivery system versus best available care in patients with unresectable metastatic uveal melanoma: Randomized FOCUS trial results.	Jonathan Zager
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #309	Abstract 9525 - Randomized phase II evaluation of nivolumab (nivo), or relatlimab (rela), or combined nivo-rela lead-in followed by nivo-rela as first line therapy for patients (pts) with advanced melanoma (mel).	Lilit Karapeytan
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #352	Abstract 9568 - A prognostic model based on selected cell state and cellular community scores in patients with advanced melanoma treated with immune checkpoint inhibitors (Ecotype-ICI score) as a predictor of ICI immunotherapeutic benefits.	Ahmad Tarhini
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #396	Abstract 1525 - Geographic and racial disparities in bi-specific antibodies trials access for diffuse large B-cell lymphoma.	Moazzam Shahzad
1:15 - 2:45 p.m.	S100bc	Clinical Science Symposium	Conflicts (of Interest) and Conundrums: Perspectives From the Global Oncology Community	Bruna Pellini
1:30 - 4:30 p.m.	Hall A	Poster Board #388b	Abstract TPS2090 - A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).	Peter Forsyth
1:30 - 4:30 p.m.	Hall A	Poster Board #329	Abstract 2030 - Efficacy of intrathecal delivery of peptide-pulsed type 1 conventional dendritic cell vaccine for the treatment of breast cancer-associated leptomeningeal disease in preclinical models.	Vincent Law
1:30 - 4:30 p.m.	Hall A	Poster Board #331	Abstract 2032 - Identification of pharmaceutics with selective activity against melanoma-associated leptomeningeal disease using patient-derived circulating tumor cells.	Vincent Law
1:30 - 4:30 p.m.	Hall A	Poster Board #326	Abstract 2027 - Tumor reactive T cells from the cerebrospinal fluid of patients with leptomeningeal disease from melanoma.	Yolanda Pina
1:30 - 4:30 p.m.	Hall A	Poster Board #376	Abstract 9592 - Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).	Andrew Brohl
1:30 - 4:30 p.m.	Hall A	Poster Board #220	Abstract 3075 - A novel MRI-based tumor-targeting theragnostic agent: Magnetoelectric nanoparticles in an in vivo murine KRAS/P53 pancreatic flank tumor model.	John Bryant

Sunday, June 2, 2024

Time	Location	Type	Title	Author/Presenter
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #108a	Abstract TPS1140 - Phase I/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases.	Kamran Ahmed
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #295	Abstract 4600 - Tumor fraction and copy number burden from urinary cell-free tumor DNA (utDNA) to predict minimal residual disease prior to repeat-transurethral resection in high-risk non-muscle invasive bladder cancer (HR-NMIBC).	Joshua Minscott
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #185	Abstract 593 - Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.	Humaira Sarfraz
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #430a	Abstract TPS6115 - A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).	Kedar Kirtane
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #292	Abstract 4597 - Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis.	Roger Li
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #296	Abstract 4601 - Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.	Roger Li
11:30 a.m. - 12:45 p.m.	S406	Rapid Oral Abstract Session	Developmental Therapeutics—Immunotherapy	Hatem Soliman
11:30 a.m. - 12:45 p.m.	Arie Crown Theater	Education Session	Neoadjuvant Approach to Localized Colon Cancer: Ready for Prime Time?	Richard Kim
11:30 a.m. - 12:45 p.m.	E450b	Education Session	Updates on Novel Therapy for Treatment of TP53-Mutated Myeloid Malignancies	David Sallman
11:30 a.m. - 1:00 p.m.	S406	Rapid Oral Abstract Session	Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers	Alberto Chiappori
4:30 - 6:00 p.m.	Hall D1	Education Session	Balancing Hormone Therapy: Minimizing Effects of Androgen Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management	Brian Gonzalez

Monday, June 3, 2024

Time	Location	Type	Title	Author/Presenter
9:00 a.m. - 12:00 p.m.	E451	Oral Abstract Session	Safety, tolerability and efficacy of 212Pb-DOTAMTATE as a targeted alpha therapy for subjects with unresectable or metastatic somatostatin receptor-expressing gastroenteropancreatic neuroendocrine tumors (SSTR+ GEP-NETs): A phase 2 study.	Jonathan Strosberg
9:00 a.m. - 12:00 p.m.	Hall A	Poster Board #343	Abstract 11148 - Timing of EGFR or ALK inhibitor initiation and survival among patients with advanced NSCLC.	Tawee Tanvetyanon
9:45 - 11:15 a.m.	Hall A	Poster Board #161	Abstract 7524 - Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.	Allison Graeter
1:30 - 4:30 p.m.	Arie Crown Theater	Case-Based Panel	Multidisciplinary Approach to Navigating Early-Stage Rectal Cancer	Seth Felder (panelist)
3:00 - 4:00 p.m.	Hall A	Poster Board #490	Abstract 8545 - A phase II trial of AZD1775 plus carboplatin-paclitaxel in squamous cell lung cancer (SqCLC).	Bruna Pellini

Publication Only

Title	Author
Real-world adherence and healthcare resource utilization of Bruton tyrosine kinase inhibitors (BTKi) in mantle cell lymphoma.	Bijal Shah
Unveiling the nexus: Use of e-frailty index in predicting chemotherapy tolerance in older patients with pancreatic cancer.	Mohammed Al-Jumayli
Concurrent enhancer of Zeste homolog 2 (EZH2) over-expression with BRAFV600E mutation predicts a poor outcome in patients with Langerhans cell histiocytosis (LCH): A pilot study.	Aditi Saha
Real-world evaluation of treatment pattern, time to next treatment (TTNT), healthcare resource utilization (HCRU), and cost of care in follicular lymphoma (FL).	Sameh Gaballa
Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in CLL/SLL.	Javier Pinilla-Ibarz
Daily diary engagement among caregivers of patients undergoing hematopoietic stem cell transplant.	Ranjita Poudel
On improving clinical trial diversity: Viewpoints from underrepresented breast cancer survivors.	Kimberley Lee
Gender disparities in Waldenstrom macroglobulinemia: Insights from a comprehensive analysis.	David Kaldas
Esophageal cancer in the United States: A 21-year mortality analysis (1999-2020).	Muhammad Zain Farooq
Bevacizumab combination therapy versus standard chemotherapy for ovarian cancer in shorter and longer followup duration: A systematic review and meta-analysis of randomized controlled trials.	Muhammad Zain Farooq
Safety outcomes in adult patients with AML who achieved their first complete remission with GO prior to HSCT.	Nelli Bejanyan

Moffitt Presentations at ASCO 2024

Note - all times are listed as CST

Cambiar el idioma